/Abbvie%20Inc%20logo%20and%20stock%20chart-by%20IgorGolovniov%20via%20Shutterstock.jpg)
AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.
Revenue growth during what should be a disastrous patent cliff is encouraging.
Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.
The company is grappling with losing Humira's patent protection in 2023.
These companies offer above-average income streams that should continue rising.
The big drugmaker went on a holiday shopping spree.
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE)....